In a nutshell This article reviewed the risk of patients with advanced Hodgkin lymphoma (HL) developing neutropenia after first-line treatment. This study concluded that this condition can be a serious complication for these patients. Some background The most commonly used frontline chemotherapy regimens for advanced HL are ABVD (doxorubicin,...
Read More
In a nutshell This study evaluated whether PET scanning during treatment can help predict outcomes for older patients with Hodgkin’s lymphoma (HL). This study concluded that PET scanning during treatment was highly predictive of outcomes for these patients. Some background Medical imaging is used during treatment (interim) to evaluate how...
Read More
In a nutshell This study assessed the usefulness of PET scanning in determining outcomes for patients with early-stage Hodgkin lymphoma (HL). This study concluded that PET scanning after chemotherapy was strongly associated with patient outcomes in early-stage HL. Some background For patients with HL, the goal of treatment is to improve outcomes...
Read More
In a nutshell This study assessed the effectiveness of nivolumab (Opdivo) alone or with chemotherapy for patients with advanced classical Hodgkin lymphoma (cHL). This study concluded that nivolumab plus chemotherapy was promising, with manageable side effects for these patients. Some background Standard first-line chemotherapy is highly effective...
Read More
In a nutshell This study evaluated the effectiveness of radiation, chemotherapy, or both for the treatment of early-stage nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL). This study concluded that long-term outcomes were favorable across all treatment approaches. Some background NLPHL is a rare subtype of non-Hodgkin's lymphoma....
Read More
In a nutshell This phase 2 study evaluated the impact of pembrolizumab (Keytruda) on the quality of life of patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. This study concluded that the overall quality of life and health status was improved for these patients. Some background Most patients...
Read More
In a nutshell This study examined how well brentuximab vedotin (Adcetris) plus high-dose bendamustine (Treanda) worked in patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL). This study concluded that this regimen was highly effective for these patients. Some background After initial treatment, many patients with cHL...
Read More
In a nutshell This phase 2 study evaluated the effectiveness and safety of camrelizumab alone or in combination with decitabine (Dacogen) for recurrent or non-responsive classical Hodgkin’s lymphoma (cHL). This study concluded that the combined treatment was safe and highly effective in these patients. Some background Standard first-line...
Read MoreIn a nutshell This phase 2 trial is evaluating how well CD8+ memory T-cell therapy works in patients with leukemia or lymphoma after a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have full chimerism (donor cells work completely and only donor cells can be identified after transplant) after therapy. This...
Read MoreIn a nutshell This study is evaluating the effectiveness of brentuximab vedotin (Adcetris) plus chemotherapy for children with advanced Hodgkin lymphoma (HL). The main outcome to be measured will be the number of patients who respond to treatment. The details Brentuximab vedotin is being tested to treat children who have advanced HL. Brentuximab...
Read More
In a nutshell This study aimed to investigate the role of positron emission tomography (PET; an imaging technique) in determining the outcomes for patients with Hodgkin lymphoma treated with chemotherapy. This study concluded that negative-PET scans after chemotherapy predict good outcomes for these patients, regardless of stage at...
Read More
Since the Human Genome Project published the first draft of the human genome in February 2001, there has been a boom in research and new technologies around genetics. The project revealed that humans have around 20,500 genes. Around 3 million base pairs make up these genes. CRISPR is a new technology that has arisen from this groundbreaking Human Genome...
Read More
